Literature DB >> 2439797

Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay.

A Wellstein, D Palm, G G Belz, G Leopold, K U Bühring, J Pabst.   

Abstract

After oral administration of single doses of 240 mg of (+/-)propranolol (prop), 200 mg of (+/-)-atenolol (aten), and 100 mg of (+/-)-bisoprolol (biso) to six healthy male volunteers, the plasma concentration time profile was investigated. To measure total plasma concentrations of the parent racemic mixture of drug administered, a HPLC-assay of drug concentrations was used. To detect active metabolites and stereoselective pharmacokinetics of the racemates, plasma concentrations were also monitored by means of a subtype-selective receptor assay, using a beta 1-adrenoceptor preparation from rat salivary glands. It is shown that relevant amounts of active metabolites do not become apparent for either of the three drugs investigated. Furthermore, for neither of them can significant stereoselective elimination characteristics be seen. Monophasic elimination characteristics with t1/2 of 4.8 +/- 0.42 (prop), 6.87 +/- 0.46 (aten), and 9.19 +/- 0.38 h (biso) become apparent. The maximum concentrations observed after administration of the doses mentioned previously were 220 +/- 71 (prop), 904 +/- 104 (aten), and 445 +/- 32 (biso) (ng/ml plasma). One can conclude from comparison with the results from receptor-binding studies that the 100 mg dose of biso is five- to seven-fold more potent than the 200 mg dose of aten, with respect to antagonism versus beta 1-adrenoceptor-mediated effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2439797     DOI: 10.1097/00005344-198511001-00007

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Experience with bisoprolol in long-QT1 and long-QT2 syndrome.

Authors:  Christian Steinberg; Gareth J Padfield; Basil Al-Sabeq; Arnon Adler; John A Yeung-Lai-Wah; Charles R Kerr; Marc W Deyell; Jason G Andrade; Matthew T Bennett; Raymond Yee; George J Klein; Martin Green; Zachary W M Laksman; Andrew D Krahn; Santabhanu Chakrabarti
Journal:  J Interv Card Electrophysiol       Date:  2016-07-09       Impact factor: 1.900

2.  A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension.

Authors:  M S Dixon; P Thomas; D J Sheridan
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Radioreceptor assay of metoprolol in human plasma: comparison with an enantiospecific high-performance liquid chromatographic (HPLC) procedure.

Authors:  H Spahn; A Wellstein; G Pflugmann; E Mutschler; D Palm
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

4.  Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

Authors:  P A Soons; C Grib; D D Breimer; W Kirch
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

5.  Receptor occupancy in lumbar CSF as a measure of the antagonist activity of atenolol, metoprolol and propranolol in the CNS.

Authors:  T Kaila; R Marttila
Journal:  Br J Clin Pharmacol       Date:  1993-05       Impact factor: 4.335

6.  Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors.

Authors:  A Wellstein; H F Pitschner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-07       Impact factor: 3.000

Review 7.  Bisoprolol in the treatment of chronic heart failure.

Authors:  Pascal de Groote; Pierre-Vladimir Ennezat; Fréderic Mouquet
Journal:  Vasc Health Risk Manag       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.